Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor

被引:23
|
作者
Hu, Wei-Hui [1 ,2 ,3 ,4 ]
Dai, Diana Kun [2 ,3 ,4 ]
Zheng, Brody Zhong-Yu [2 ,3 ,4 ]
Duan, Ran [2 ,3 ,4 ]
Dong, Tina Ting-Xia [2 ,3 ,4 ]
Qin, Qi-Wei [1 ]
Tsim, Karl Wah-Keung [2 ,3 ,4 ]
机构
[1] South China Agr Univ, Coll Marine Sci, Joint Lab Guangdong Prov & Hong Kong Reg Marine B, Guangzhou 510642, Peoples R China
[2] Hong Kong Univ Sci & Technol, Shenzhen Key Lab Edible & Med Bioresources, Hitech Pk, Shenzhen 518057, Peoples R China
[3] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong 999077, Peoples R China
[4] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Hong Kong 999077, Peoples R China
来源
MOLECULES | 2020年 / 25卷 / 17期
基金
中国博士后科学基金;
关键词
piceatannol; herbal medicine; vasculogenesis; VEGF; VEGFR2; pure compound; TYROSINE KINASE; ANTIANGIOGENIC THERAPY; SIGNAL-TRANSDUCTION; CELL-DEATH; CANCER; APOPTOSIS; STILBENE; KDR; IDENTIFICATION; MECHANISMS;
D O I
10.3390/molecules25173769
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Piceatannol is also named astrans-3,4,3 ',5 '-tetrahydroxy-stilbene, which is a natural analog of resveratrol and a polyphenol existing in red wine, grape and sugar cane. Piceatannol has been proved to possess activities of immunomodulatory, anti-inflammatory, antiproliferative and anticancer. However, the effect of piceatannol on VEGF-mediated angiogenesis is not known. Here, the inhibitory effects of piceatannol on VEGF-induced angiogenesis were tested both in vitro and in vivo models of angiogenesis. In human umbilical vein endothelial cells (HUVECs), piceatannol markedly reduced the VEGF-induced cell proliferation, migration, invasion, as well as tube formation without affecting cell viability. Furthermore, piceatannol significantly inhibited the formation of subintestinal vessel in zebrafish embryos in vivo. In addition, we identified the underlying mechanism of piceatannol in triggering the anti-angiogenic functions. Piceatannol was proposed to bind with VEGF, thus attenuating VEGF in activating VEGF receptor and blocking VEGF-mediated downstream signaling, including expressions of phosphorylated eNOS, Erk and Akt. Furthermore, piceatannol visibly suppressed ROS formation, as triggered by VEGF. Moreover, we further determined the outcome of piceatannol binding to VEGF in cancer cells: piceatannol significantly suppressed VEGF-induced colon cancer proliferation and migration. Thus, these lines of evidence supported the conclusion that piceatannol could down regulate the VEGF-mediated angiogenic functions with no cytotoxicity via decreasing the amount of VEGF binding to its receptors, thus affecting the related downstream signaling. Piceatannol may be developed into therapeutic agents or health products to reduce the high incidence of angiogenesis-related diseases.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
    Chatterjee, Subhojyoti
    Bhattacharjee, Biplab
    [J]. BIOINFORMATION, 2012, 8 (25) : 1249 - 1254
  • [2] Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy
    Veeravagu, Anand
    Hsu, Andrew R.
    Cai, Weibo
    Hou, Lewis C.
    Tse, Victor C. K.
    Chen, Xiaoyuan
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (01) : 59 - 71
  • [3] Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis
    Li, Tao
    Liu, Xiaoxia
    Shen, Qin
    Yang, Wenjun
    Huo, Zhenghao
    Liu, Qilun
    Jiao, Haiyan
    Chen, Jing
    [J]. ONCOTARGET, 2016, 7 (18) : 26580 - 26592
  • [4] Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
    Niu, Gang
    Chen, Xiaoyuan
    [J]. CURRENT DRUG TARGETS, 2010, 11 (08) : 1000 - 1017
  • [5] Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells
    Akel, SM
    Atoum, MF
    Saleh, SA
    Awadallah, SM
    [J]. SAUDI MEDICAL JOURNAL, 2005, 26 (10) : 1523 - 1528
  • [6] Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules
    Zachary, I
    [J]. IDRUGS, 2003, 6 (03) : 224 - 231
  • [7] Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy
    Pasqualetti, Giuseppe
    Danesi, Romano
    Del Tacca, Mario
    Bocci, Guido
    [J]. PHARMACOGENOMICS, 2007, 8 (01) : 49 - 66
  • [8] Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects
    Bakri, Sophie J.
    Lynch, Jeff
    Howard-Sparks, Michelle
    Saint-Juste, Stephan
    Saim, Said
    [J]. PLOS ONE, 2024, 19 (06):
  • [9] Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy
    Underiner, TL
    Ruggeri, B
    Gingrich, DE
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) : 731 - 745
  • [10] Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
    Falcon, Beverly L.
    Chintharlapalli, Sudhakar
    Uhlik, Mark T.
    Pytowski, Bronislaw
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 204 - 225